Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keating, M. J.
Right arrow Articles by Rai, K. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keating, M. J.
Right arrow Articles by Rai, K. R.
Related Collections
Right arrow Neoplasia
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 15 May 2002, Vol. 99, No. 10, pp. 3554-3561

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

Michael J. Keating, Ian Flinn, Vinay Jain, Jacques-Louis Binet, Peter Hillmen, John Byrd, Maher Albitar, Lee Brettman, Pedro Santabarbara, Bret Wacker, and Kanti R. Rai

From the M. D. Anderson Cancer Center, Houston, TX; Johns Hopkins Institute, Baltimore, MD; Texas Oncology P.A., Austin, TX; Hôpital Pitié Salpetrière, Paris, France; Leeds General Infirmary, Leeds, United Kingdom; Ohio State University, Columbus; Millennium Pharmaceuticals, Cambridge, MA; Ilex Oncology, San Antonio, TX; and Long Island Jewish Medical Center, New Hyde Park, NY.

This study investigated the efficacy, safety, and clinical benefit of alemtuzumab (Campath-1H) for patients with relapsed or refractory B-cell chronic lymphocytic leukemia exposed to alkylating agents and having failed fludarabine therapy. Ninety-three patients received alemtuzumab in 21 centers worldwide, with the aim to obtain an overall response rate of at least 20%. Dosage was increased gradually (target 30 mg, 3 times weekly, for a maximum of 12 weeks). Infection prophylaxis was mandatory, beginning on day 8, and continuing for a minimum of 2 months after treatment. Responses were assessed at weeks 4, 8, and 12, and patients were followed for 34 months. Overall objective response in the intent-to-treat population (n = 93) was 33% (CR 2%, PR 31%). Median time to response was 1.5 months (range, 0.4-3.7 months). Median time to progression was 4.7 months overall, 9.5 months for responders. At data cut-off, 27 patients (29%) were alive; overall median survival was 16 months (95% CI: 11.8-21.9) and 32 months for responders. Nineteen responders survived more than 21 months. Clinical benefit was observed both in responders and in patients with stable disease. The most common adverse events were related to infusion, generally grade 1 or 2 in severity, occurring mainly in the first week. Grade 3 or 4 infections were reported in 25 patients (26.9%). However, only 3 (9.7%) of 31 patients who responded to alemtuzumab treatment developed grade 3 or 4 infections on the study. Alemtuzumab induced significant responses in these patients with clinical benefit in the majority and with acceptable toxicity in a high-risk group.

© 2002 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
M. A. Phelps, T. S. Lin, A. J. Johnson, E. Hurh, D. M. Rozewski, K. L. Farley, D. Wu, K. A. Blum, B. Fischer, S. M. Mitchell, et al.
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
Blood, March 19, 2009; 113(12): 2637 - 2645.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S. J. Kim, K. Kim, B. S. Kim, C. Suh, J. Huh, Y. H. Ko, and W. S. Kim
Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study
Ann. Onc., February 1, 2009; 20(2): 390 - 392.
[Full Text] [PDF]


Home page
haematolHome page
T. Elter, J. Kilp, P. Borchmann, H. Schulz, M. Hallek, and A. Engert
Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia
Haematologica, January 1, 2009; 94(1): 150 - 152.
[Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
C Agostinelli, P P Piccaluga, P Went, M Rossi, A Gazzola, S Righi, T Sista, C Campidelli, P L Zinzani, B Falini, et al.
Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies
J. Clin. Pathol., November 1, 2008; 61(11): 1160 - 1167.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. L. Sorror, B. E. Storer, B. M. Sandmaier, M. Maris, J. Shizuru, R. Maziarz, E. Agura, T. R. Chauncey, M. A. Pulsipher, P. A. McSweeney, et al.
Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning
J. Clin. Oncol., October 20, 2008; 26(30): 4912 - 4920.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. Tan, S. Yang, J. Cai, J. Guo, L. Huang, Z. Wu, J. Chen, and L. Liao
Simultaneous Islet and Kidney Transplantation in Seven Patients With Type 1 Diabetes and End-Stage Renal Disease Using a Glucocorticoid-Free Immunosuppressive Regimen With Alemtuzumab Induction
Diabetes, October 1, 2008; 57(10): 2666 - 2671.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
B. D. Cheson and J. P. Leonard
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
N. Engl. J. Med., August 7, 2008; 359(6): 613 - 626.
[Full Text] [PDF]


Home page
BloodHome page
A. Ferrajoli, B.-N. Lee, E. J. Schlette, S. M. O'Brien, H. Gao, S. Wen, W. G. Wierda, Z. Estrov, S. Faderl, E. N. Cohen, et al.
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
Blood, June 1, 2008; 111(11): 5291 - 5297.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. K. Oldham and R. O. Dillman
Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress
J. Clin. Oncol., April 10, 2008; 26(11): 1774 - 1777.
[Full Text] [PDF]


Home page
BloodHome page
S. O'Brien, F. Ravandi, T. Riehl, W. Wierda, X. Huang, J. Tarrand, B. O'Neal, H. Kantarjian, and M. Keating
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy
Blood, February 15, 2008; 111(4): 1816 - 1819.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Lapalombella, X. Zhao, G. Triantafillou, B. Yu, Y. Jin, G. Lozanski, C. Cheney, N. Heerema, D. Jarjoura, A. Lehman, et al.
A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents
Clin. Cancer Res., January 15, 2008; 14(2): 569 - 578.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
W. G. Wierda
Treatments for Patients with Chronic Lymphocytic Leukemia
ASCO Educational Book, January 1, 2008; 2008(1): 297 - 305.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Hillmen, A. B. Skotnicki, T. Robak, B. Jaksic, A. Dmoszynska, J. Wu, C. Sirard, and J. Mayer
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia
J. Clin. Oncol., December 10, 2007; 25(35): 5616 - 5623.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. M. Flynn and J. C. Byrd
Have We Forgotten the Purpose of Phase III Studies?
J. Clin. Oncol., December 10, 2007; 25(35): 5553 - 5555.
[Full Text] [PDF]


Home page
Br Med BullHome page
C. E. Dearden
Role of antibody therapy in lymphoid malignancies
Br. Med. Bull., September 1, 2007; 83(1): 275 - 290.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. C. Byrd, S. O'Brien, I. W. Flinn, T. J. Kipps, M. Weiss, K. Rai, T. S. Lin, J. Woodworth, D. Wynne, J. Reid, et al.
Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Clin. Cancer Res., August 1, 2007; 13(15): 4448 - 4455.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. Hosen, C. Y. Park, N. Tatsumi, Y. Oji, H. Sugiyama, M. Gramatzki, A. M. Krensky, and I. L. Weissman
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
PNAS, June 26, 2007; 104(26): 11008 - 11013.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
M. G. Bernengo, P. Quaglino, A. Comessatti, M. Ortoncelli, M. Novelli, F. Lisa, and M. T. Fierro
Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients
Haematologica, June 1, 2007; 92(6): 784 - 794.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. C. Byrd, T. S. Lin, J. T. Dalton, D. Wu, M. A. Phelps, B. Fischer, M. Moran, K. A. Blum, B. Rovin, M. Brooker-McEldowney, et al.
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
Blood, January 15, 2007; 109(2): 399 - 404.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
V. A. Morrison
Management of Infectious Complications in Patients with Chronic Lymphocytic Leukemia
Hematology, January 1, 2007; 2007(1): 332 - 338.
[Abstract] [Full Text] [PDF]


Home page
ASH-SAPHome page
P. Venugopal and S. A. Gregory
Lymphoproliferative disorders
ASH Self-Assessment Program, January 1, 2007; 2007(1): 265 - 297.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. J. Rodig, J. S. Abramson, G. S. Pinkus, S. P. Treon, D. M. Dorfman, H. Y. Dong, M. A. Shipp, and J. L. Kutok
Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H)
Clin. Cancer Res., December 1, 2006; 12(23): 7174 - 7179.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Stein, Z. Qu, S. Chen, D. Solis, H. J. Hansen, and D. M. Goldenberg
Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab
Blood, October 15, 2006; 108(8): 2736 - 2744.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
K. W. L. Yee and S. M. O'Brien
Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc., August 1, 2006; 81(8): 1105 - 1129.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. Sandherr, H. Einsele, H. Hebart, C. Kahl, W. Kern, M. Kiehl, G. Massenkeil, O. Penack, X. Schiel, S. Schuettrumpf, et al.
Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO)
Ann. Onc., July 1, 2006; 17(7): 1051 - 1059.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Montillo, A. Tedeschi, S. Miqueleiz, S. Veronese, R. Cairoli, L. Intropido, F. Ricci, A. Colosimo, B. Scarpati, M. Montagna, et al.
Alemtuzumab As Consolidation After a Response to Fludarabine Is Effective in Purging Residual Disease in Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol., May 20, 2006; 24(15): 2337 - 2342.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Montserrat, C. Moreno, J. Esteve, A. Urbano-Ispizua, E. Gine, and F. Bosch
How I treat refractory CLL
Blood, February 15, 2006; 107(4): 1276 - 1283.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Delgado, K. Thomson, N. Russell, J. Ewing, W. Stewart, G. Cook, S. Devereux, R. Lovell, R. Chopra, D. I. Marks, et al.
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study
Blood, February 15, 2006; 107(4): 1724 - 1730.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
W. G. Wierda
Current and Investigational Therapies for Patients with CLL
Hematology, January 1, 2006; 2006(1): 285 - 294.
[Abstract] [Full Text] [PDF]


Home page
ASH ANNUAL MEETING ABSTRACTSHome page
M. Egyed, B. Kollar, E. Karadi, G. Rumi, and L. Kereskai
A Case Study of a Patient with Chemotherapy Resistant CLL Successfully Retreated with Alemtuzumab.
Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 5037 - 5037.
[Abstract]


Home page
JCOHome page
T. Elter, P. Borchmann, H. Schulz, M. Reiser, S. Trelle, R. Schnell, M. Jensen, P. Staib, T. Schinkothe, H. Stutzer, et al.
Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial
J. Clin. Oncol., October 1, 2005; 23(28): 7024 - 7031.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. T. Wong
Management of Central Nervous System Lymphomas Using Monoclonal Antibodies: Challenges and Opportunities
Clin. Cancer Res., October 1, 2005; 11(19): 7151s - 7157s.
[Abstract] [Full Text] [PDF]


Home page
Phil Trans R Soc BHome page
H. Waldmann and G. Hale
CAMPATH: from concept to clinic
Phil Trans R Soc B, September 29, 2005; 360(1461): 1707 - 1711.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. G. Wierda, T. J. Kipps, and M. J. Keating
Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia
J. Clin. Oncol., September 10, 2005; 23(26): 6325 - 6332.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Z. Pavletic, I. F. Khouri, M. Haagenson, R. J. King, P. J. Bierman, M. R. Bishop, M. Carston, S. Giralt, A. Molina, E. A. Copelan, et al.
Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research
J. Clin. Oncol., August 20, 2005; 23(24): 5788 - 5794.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. S. Lin, M. R. Grever, and J. C. Byrd
Changing the Way We Think About Chronic Lymphocytic Leukemia
J. Clin. Oncol., June 20, 2005; 23(18): 4009 - 4012.
[Full Text] [PDF]


Home page
JCOHome page
W. Wierda, S. O'Brien, S. Wen, S. Faderl, G. Garcia-Manero, D. Thomas, K.-A. Do, J. Cortes, C. Koller, M. Beran, et al.
Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia
J. Clin. Oncol., June 20, 2005; 23(18): 4070 - 4078.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. L. Sorror, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. J. Stuart, U. Hegenbart, E. Agura, T. R. Chauncey, J. Leis, M. Pulsipher, et al.
Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia
J. Clin. Oncol., June 1, 2005; 23(16): 3819 - 3829.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. C. Byrd, B. L. Peterson, J. Gabrilove, O. M. Odenike, M. R. Grever, K. Rai, R. A. Larson, and the Cancer and Leukemia Group B
Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805
Clin. Cancer Res., June 1, 2005; 11(11): 4176 - 4181.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Moreton, B. Kennedy, G. Lucas, M. Leach, S. M.B. Rassam, A. Haynes, J. Tighe, D. Oscier, C. Fegan, A. Rawstron, et al.
Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival
J. Clin. Oncol., May 1, 2005; 23(13): 2971 - 2979.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. D. Shanafelt, Y. K. Lee, N. D. Bone, A. K. Strege, V. L. Narayanan, E. A. Sausville, S. M. Geyer, S. H. Kaufmann, and N. E. Kay
Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine
Blood, March 1, 2005; 105(5): 2099 - 2106.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
M. Hallek and On Behalf Of The German CLL Study Group
Chronic Lymphocytic Leukemia (CLL): First-Line Treatment
Hematology, January 1, 2005; 2005(1): 285 - 291.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J. G. Gribben
Salvage Therapy for CLL and the Role of Stem Cell Transplantation
Hematology, January 1, 2005; 2005(1): 292 - 298.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. S. Lin, I. W. Flinn, R. Modali, T. A. Lehman, J. Webb, S. Waymer, M. E. Moran, M. S. Lucas, S. S. Farag, and J. C. Byrd
FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
Blood, January 1, 2005; 105(1): 289 - 291.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. Christiansen and A. K. Rajasekaran
Biological impediments to monoclonal antibody-based cancer immunotherapy
Mol. Cancer Ther., November 1, 2004; 3(11): 1493 - 1501.
[Abstract] [Full Text] [PDF]


Home page
CA Cancer J ClinHome page
B. D. Cheson
What Is New in Lymphoma?
CA Cancer J Clin, September 1, 2004; 54(5): 260 - 272.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Hale, P. Rebello, L. R. Brettman, C. Fegan, B. Kennedy, E. Kimby, M. Leach, J. Lundin, H. Mellstedt, P. Moreton, et al.
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
Blood, August 15, 2004; 104(4): 948 - 955.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. J. Lenihan, A. J. Alencar, D. Yang, R. Kurzrock, M. J. Keating, and M. Duvic
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome
Blood, August 1, 2004; 104(3): 655 - 658.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. Hong, J. Yan, J. T. Baran, D. J. Allendorf, R. D. Hansen, G. R. Ostroff, P. X. Xing, N.-K. V. Cheung, and G. D. Ross
Mechanism by Which Orally Administered {beta}-1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models
J. Immunol., July 15, 2004; 173(2): 797 - 806.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
A. J. Olszewski and M. L. Grossbard
Empowering Targeted Therapy: Lessons from Rituximab
Sci. Signal., July 13, 2004; 2004(241): pe30 - pe30.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Lozanski, N. A. Heerema, I. W. Flinn, L. Smith, J. Harbison, J. Webb, M. Moran, M. Lucas, T. Lin, M. L. Hackbarth, et al.
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
Blood, May 1, 2004; 103(9): 3278 - 3281.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Stein, Z. Qu, S. Chen, A. Rosario, V. Shi, M. Hayes, I. D. Horak, H. J. Hansen, and D. M. Goldenberg
Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma
Clin. Cancer Res., April 15, 2004; 10(8): 2868 - 2878.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Enblad, H. Hagberg, M. Erlanson, J. Lundin, A. P. MacDonald, R. Repp, J. Schetelig, G. Seipelt, and A. Osterborg
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
Blood, April 15, 2004; 103(8): 2920 - 2924.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Dreger, S. Stilgenbauer, A. Benner, M. Ritgen, A. Krober, M. Kneba, N. Schmitz, and H. Dohner
The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status
Blood, April 1, 2004; 103(7): 2850 - 2858.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. C. Rawstron, B. Kennedy, P. Moreton, A. J. Dickinson, M. J. Cullen, S. J. Richards, A. S. Jack, and P. Hillmen
Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia
Blood, March 15, 2004; 103(6): 2027 - 2031.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
A. L. Basquiera, A. R. Berretta, J. J. Garcia, and E. D. Palazzo
Coronary ischemia related to alemtuzumab therapy
Ann. Onc., March 1, 2004; 15(3): 539 - 540.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
T. D. Shanafelt and T. G. Call
Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia
Mayo Clin. Proc., March 1, 2004; 79(3): 388 - 398.
[Abstract] [PDF]


Home page
ASH Education BookHome page
J. C. Byrd, S. Stilgenbauer, and I. W. Flinn
Chronic Lymphocytic Leukemia
Hematology, January 1, 2004; 2004(1): 163 - 183.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
I. M. Ghobrial, L. A. Otteman, W. L. White, D. A. Rizzieri, S. Weitman, and D. M. Vaughn
An EBV-Positive Lymphoproliferative Disorder after Therapy with Alemtuzumab
N. Engl. J. Med., December 25, 2003; 349(26): 2570 - 2572.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Coleman, D. M. Goldenberg, A. B. Siegel, J. C. Ketas, M. Ashe, J. M. Fiore, and J. P. Leonard
Epratuzumab: Targeting B-Cell Malignancies through CD22
Clin. Cancer Res., September 1, 2003; 9(10): 3991S - 3994.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. J. M. Mackus, F. N. J. Frakking, A. Grummels, L. E. Gamadia, G. J. de Bree, D. Hamann, R. A. W. van Lier, and M. H. J. van Oers
Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia
Blood, August 1, 2003; 102(3): 1057 - 1063.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Kumar, T. K. Kimlinger, J. A. Lust, K. Donovan, and T. E. Witzig
Expression of CD52 on plasma cells in plasma cell proliferative disorders
Blood, August 1, 2003; 102(3): 1075 - 1077.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Lundin, H. Hagberg, R. Repp, E. Cavallin-Stahl, S. Freden, G. Juliusson, E. Rosenblad, G. Tjonnfjord, T. Wiklund, and A. Osterborg
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
Blood, June 1, 2003; 101(11): 4267 - 4272.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. C. Byrd, D. M. Lucas, A. P. Mone, J. B. Kitner, J. J. Drabick, and M. R. Grever
KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis
Blood, June 1, 2003; 101(11): 4547 - 4550.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. Mavromatis and B. D. Cheson
Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia
J. Clin. Oncol., May 1, 2003; 21(9): 1874 - 1881.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Faderl, D. A. Thomas, S. O'Brien, G. Garcia-Manero, H. M. Kantarjian, F. J. Giles, C. Koller, A. Ferrajoli, S. Verstovsek, B. Pro, et al.
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
Blood, May 1, 2003; 101(9): 3413 - 3415.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. A. Weiss, P. G. Maslak, J. G. Jurcic, D. A. Scheinberg, T. B. Aliff, N. Lamanna, S. R. Frankel, S. E. Kossman, and D. Horgan
Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol., April 1, 2003; 21(7): 1278 - 1284.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. E. Herbert, H. M. Prince, and D. A. Westerman
Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab
Blood, February 15, 2003; 101(4): 1654 - 1654.
[Full Text] [PDF]


Home page
ASH Education BookHome page
M. J. Keating, N. Chiorazzi, B. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, M. Ferrarini, and T. J. Kipps
Biology and Treatment of Chronic Lymphocytic Leukemia
Hematology, January 1, 2003; 2003(1): 153 - 175.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
S. N. O'Brien, N. M.A. Blijlevens, T. H. Mahfouz, and E. J. Anaissie
Infections in Patients with Hematological Cancer: Recent Developments
Hematology, January 1, 2003; 2003(1): 438 - 472.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. R. Rai, C. E. Freter, R. J. Mercier, M. R. Cooper, B. S. Mitchell, E. A. Stadtmauer, P. Santabarbara, B. Wacker, and L. Brettman
Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine
J. Clin. Oncol., September 15, 2002; 20(18): 3891 - 3897.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. Stilgenbauer and H. Dohner
Campath-1H-Induced Complete Remission of Chronic Lymphocytic Leukemia despite p53 Gene Mutation and Resistance to Chemotherapy
N. Engl. J. Med., August 8, 2002; 347(6): 452 - 453.
[Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020